Board of Directors
Press release archivePress Release Archive
| 2008 | Announcement |  |  |
|---|---|---|---|
| 24 October 2008 | Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco |  | |
| 29 September 2008 | Nitec Pharma AG secures funding of CHF 24M from TVM Capital and Deutsche Bank | | |
| 12 June 2008 | Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris. | | |
| 22 January 2008 | Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet. | | |
| 2007 | Announcement | ||
|---|---|---|---|
| 4 December 2007 | Nitec Pharma appoints Hans Fünfschilling as Chairman... | | |
| 8 November 2007 | Lodotra™ shows a sustained reduction of morning stiffness in patients with rheumatoid arthritis treated with Lodotra™ for 12 months | | |
| 5 November 2007 | Nitec Pharma licenses Tarenflurbil for | | |
| 4 October 2007 | Nitec Pharma expands senior management team | | |
| 24 September 2007 | Nitec’s IND application for clinical development with Lodotra™ accepted by the FDA | | |
| 3 September 2007 | Nitec Pharma AG announces appointments of CEO & CFO in preparation for launch of Lodotra™ | | |
| 29 March 2007 | Nitec Pharma AG closes CHF 32 million (approx. US$ 26 million) Series B financing led by NGN Capital | | |
| 14 February 2007 | Nitec Pharma Signs German Marketing Rights for Lodotra™ to Merck Pharma GmbH | |
| 2006 | Announcement | ||
|---|---|---|---|
| 28 September 2006 | Nitec Pharma Reports Positive Phase 3 Results and Filing in EU for Lodotra™ | |
| 2004 | Announcement | ||
|---|---|---|---|
| 1 October 2004 | Atlas Venture and Global Life Science Ventures invest in Nitec Pharma AG | |
24/10/2007
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
12/06/2008
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
